Biyolojik İlaç Kullanan Romatoloji Hastalarında HBV ve HCV Seroprevalansı

Amaç: Hepatit B virüsü (HBV) ve Hepatit C virüsü (HCV) enfeksiyonları küresel bir halk sağlığı sorunudur. Biyolojik ilaçlar, kronik HBV taşıyıcısı veya okült HBV enfeksiyonu olan hastalarda HBV enfeksiyonunun yeniden aktivasyonuna neden olabilir. Aynı şekilde Anti HCV pozitif olan hastalarda da HCV enfeksiyonunun reaktivasyonuna neden olabildiği bilinmektedir. Biz çalışmamızda biyolojik tedavi alan romatoloji hastalarında HBV ve HCV enfeksiyonlarının prevalansını araştırmayı amaçladık.Yöntemler: 01/09/2017- 01/09/2020 tarihleri arasında Diyarbakır Sağlık Bilimleri Üniversitesi Gazi Yaşargil Eğitim ve Araştırma Hastanesi Romatoloji Polikliniği’ne başvuran ve biyolojik tedavi başlanan 582 hasta çalışmaya alındı. Retrospektif olarak demografik ve labaratuar özellikleri kayıt edildi. İstatistiksel analizler SPSS V22.0 (IBM SPSS Statistics, Armonk, NY) yazılımı ile yapıldı.Bulgular: Çalışmamıza 342’si (%58,8) kadın ve 240’ı (%41,2) erkek olmak üzere toplam 582 hasta alındı. Çalışmaya alınan hastaların 290’unda (%49,8) ankilozan spondilit (AS), 213’ünde (%36,6) romatoid artrit (RA), 23’ünde (%4,0) psöriatik artrit (PsA) tanısı mevcuttu. HBsAg %1,4, Anti-HBs %51,7, Anti-HBc IgG %31,4 ve Anti-HCV %0,3 oranlarında pozitif saptandı. Tanılara göre bakınca; AS’de HBsAg %1,7, Anti-HBs %53,1, Anti-HBc IgG %38,9, Anti-HCV %0,0, RA’da HBsAg %1,4, Anti-HBs %51,9, Anti-HBc IgG %41,7, Anti-HCV %0,5 oranlarında saptandı.Sonuç: Ülkemizde hala HBV ve HCV enfeksiyonları orta endemik seviyede görülmektedir. Biyolojik tedaviler HBV ve HCV enfeksiyonlarının reaktivasyonuna neden olabileceğinden biyolojik tedavi öncesi bu enfeksiyonların taranması, profilaksisi ve tedavisi önemini hala korumaktadır.

HBV and HCV Seroprevalence in Rheumatology Patients Using Biological Drugs

Objective: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are a global public health problem. Biological drugs can cause reactivation of HBV infection in patients with chronic HBV carrier or occult HBV infection. Likewise, it is known that it can cause reactivation of HCV infection in patients who are positive for Anti HCV. In our study, we aimed to investigate the prevalence of HBV and HCV infections in rheumatology patients receiving biological therapy. Method: 582 patients who applied to Diyarbakır Health Sciences University Gazi Yaşargil Training and Research Hospital Rheumatology Polyclinic between 01/09/2017 and 01/09/2020 and using biological treatment were included in the study. Demographic and laboratory characteristics were recorded retrospectively. Statistical analysis was performed with SPSS V22.0 (IBM SPSS Statistics, Armonk, NY) software. Results: A total of 582 patients, 342 (58.8%) female and 240 (41.2%) male, were included in our study. Of the patients included in the study, 290 (49.8%) were diagnosed with ankylosing spondylitis (AS), 213 (36.6%) rheumatoid arthritis (RA), and 23 (4%) psoriatic arthritis (PsA). HBsAg 1.4%, Anti-HBs 51.7%, Anti-HBc IgG 31.4% and Anti-HCV 0.3% were positive. Looking according to the diagnosis; In AS; HBsAg 1.7%, Anti-HBs 53.1%, Anti-HBc IgG 38.9%, Anti-HCV 0.0%, in RA; HBsAg was 1.4%, Anti-HBs 51.9%, Anti-HBc IgG 41.7%, Anti-HCV 0.5% were detected. Conclusion: In our country, HBV and HCV infections are still seen at medium endemic levels. Since biological treatments may cause reactivation of HBV and HCV infections, screening, prophylaxis and treatment of these infections before biological treatment still maintains its importance.

PDF

___

1.Hepatitis B [https://www.who.int/news-room/fact-sheets/detail/hepatitis-b]
2.Hepatitis C [https://www.who.int/news-room/fact-sheets/detail/hepatitis-c]
3.Tozun N, Ozdogan O, Cakaloglu Y, et al.Seroprevalence of hepatitis B and C virus infectionsand risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015; 21: 1020-6.
4.Smolen JS, Landewe R, Bijlsma J, et al. EULARrecommendations for the management ofrheumatoid arthritis with synthetic and biologicaldisease-modifying antirheumatic drugs: 2016update. Ann Rheum Dis. 2017; 76: 960-77.
5.Sharma SK. Use of Biologics and Biosimilars inRheumatology. J Assoc Physicians India. 2017; 65: 9-14.
6.Su J, Long L, Zou K. Antiviral prophylaxis forpreventing reactivation of hepatitis B virus inrheumatic patients: a systematic review and meta-analysis. Clin Rheumatol. 2018; 37: 3201-14.
7.Mok CC. Hepatitis B and C infection in patientsundergoing biologic and targeted therapies forrheumatic diseases. Best Pract Res Clin Rheumatol.2018; 32: 767-80.
8.Chiu YM, Lai MS, Chan KA. Commensurateincidence and outcomes of liver enzyme elevationbetween anti-tumor necrosis factor users with orwithout prior hepatitis B virus infections. PLoS One.2018; 13: e0196210.
9.Özekinci T, Atmaca S, Akpolat N, Gül K. GüneydoğuAnadolu Bölgesi’nde Rutin Hepatit B AşıProgramının Etkisi. Dicle Tıp Dergisi / Dicle MedicalJournal. 2017; 44: 283-5.
10.Schwaneck EC, Krone M, Kreissl-Kemmer S, et al.Management of anti-HBc-positive patients withrheumatic diseases treated with disease-modifyingantirheumatic drugs-a single-center analysis of2054 patients. Clin Rheumatol. 2018; 37: 2963-70.
11.Su YC, Lin PC, Yu HC, Wu CC. Hepatitis B virusreactivation in patients with resolved hepatitis Bvirus infection receiving chemotherapy orimmunosuppressive therapy. Eur J GastroenterolHepatol. 2018; 30: 925-9.
12.Zheng B, Li T, Lin Q, et al. Prevalence of hepatitisB surface antigen in patients with ankylosingspondylitis and its association with HLA-B27: aretrospective study from south China. RheumatolInt. 2012; 32: 2011-6.
13.Yilmaz N, Karadag O, Kimyon G et al. Prevalenceof hepatitis B and C infections in rheumatoid arthritis and ankylosing spondylitis: A multicenter countrywide study. Eur J Rheumatol. 2014; 1: 51-4.
14.Matsuzaki T, Eguchi K, Nagao N et al. Hepatitis Bvirus reactivation in patients with rheumatoidarthritis: A single-center study. Mod Rheumatol.2018; 28: 808-13.
15.Ballanti E, Conigliaro P, Chimenti MS et al. Use ofanti-tumor necrosis factor alpha therapy in patientswith concurrent rheumatoid arthritis and hepatitisB or hepatitis C: a retrospective analysis of 32patients. Drug Dev Res. 2014;75 Suppl 1: S42-5.
16.Morisco F, Guarino M, La Bella S, et al. Lack ofevidence of viral reactivation in HBsAg-negativeHBcAb-positive and HCV patients undergoingimmunosuppressive therapy for psoriasis. BMCGastroenterol. 2014; 14: 214.
17.Zhao J, Qiu M, Li M, Lu C, Gu J. Low prevalence ofhepatitis B virus infection in patients with systemiclupus erythematosus in southern China. RheumatolInt. 2010; 30: 1565-70.
18.Chen MH, Chen MH, Tsai CY, et al. Incidence andantiviral response of hepatitis C virus reactivation inlupus patients undergoing immunosuppressivetherapy. Lupus. 2015; 24: 1029-36.